Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis

References

• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet Lond Engl. 2007;370:263–271.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516..
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases part I: epidemiology. J Am Acad Dermatol. 2017;76:377–390.
   PubMed Web of Science ®Google Scholar
• The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. - PubMed - NCBI [Internet]. [cited 2019 Dec 4]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11255325.
   Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8:235–245.
   PubMedGoogle Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659.
   PubMed Web of Science ®Google Scholar
• Papp K, Gulliver W, Lynde C, et al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15:210–219.
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol JEADV. 2012;26(Suppl 3):1–10..
   PubMedGoogle Scholar
• Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168:954–967.
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131–135.
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PCM, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316–323.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatol Basel Switz. 2002;205:389–393.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167–1173.
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatol Basel Switz. 2004;209:308–313.
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48–54.
   PubMed Web of Science ®Google Scholar
• Kragballe K. van de Kerkhof PCM. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol JEADV. 2006;20:39–44.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatol Treat. 2007;18:361–365.
   PubMed Web of Science ®Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol EJD. 2010;20:465–471.
   PubMed Web of Science ®Google Scholar
• Langley RGB, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatol Basel Switz. 2011;222:148–156.
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin. 2011;27:251–268.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol JDD. 2013;12:92–98.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol JEADV. 2014;28:1723–1731.
   PubMed Web of Science ®Google Scholar
• Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. Expert Opin Pharmacother. 2017;18:115–121.
   PubMed Web of Science ®Google Scholar
• Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9:789–797.
   PubMed Web of Science ®Google Scholar
• Lovato P, Norsgaard H, Tokura Y, et al. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81:153–164.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Iversen L. Calcipotriol: A new topical antipsoriatic. Dermatol Clin. 1993;11:137–141.
   PubMed Web of Science ®Google Scholar
• Milde P, Hauser U, Simon T, et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol. 1991;97:230–239.
   PubMed Web of Science ®Google Scholar
• Dyring-Andersen B, Bonefeld CM, Bzorek M, et al. The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions. Scand J Immunol. 2015;82:84–91.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhou R, Luger D, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol Baltim. 2009;182:4624–4632.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Perez A, Müller SM, et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. 1997;77:268–272.
   PubMed Web of Science ®Google Scholar
• Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: where are we standing and where will we be going? Dermatoendocrinol. 2011;3:180–186.
   PubMedGoogle Scholar
• Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol. 2000;18:309–345.
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018.
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. Ther Deliv. 2017;8:737–746.
   PubMed Web of Science ®Google Scholar
• Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo ex … - PubMed - NCBI [Internet]. [cited 2019 Nov 11]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27315769.
   Google Scholar
• Satake K, Amano T, Okamoto T. Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model. Sci Rep. 2019;9:16322.
   PubMed Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther. 2016;6:413–425.
   PubMed Web of Science ®Google Scholar
• Taraska V, Tuppal R, Olesen M, et al. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20:44–51.
   PubMed Web of Science ®Google Scholar
• LEO Pharma. Enstilar® (calcipotriene and betamethasone dipropionate) foam: US prescribing information. 2016. Avaliable from: http://www.leo-pharma.us/Files/Billeder/enstilar-pi%202019.pdf
   Google Scholar
• Menter A, Gold LS, Koo J, et al. Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15:119–124.
   PubMedGoogle Scholar
• Basse LH, Olesen M, Lacour JP, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol. 2014;134:S33 (abst 192).
   Web of Science ®Google Scholar
• McKENZIE AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–610.
   Web of Science ®Google Scholar
• Queille-Roussel C, Bang B, Clonier F, et al. Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs other corticosteroid psoriasis treatments. J Eur Acad Dermatol Venereol JEADV. 2016;30:1951–1956.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Nielsen J, Lacour J-P. Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris. J Dermatol Treat. 2019;30:529–533.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Olesen M, Villumsen J, et al. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35:239–245.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than cal or BD aerosol foam alone for psoriasis vulgaris. J Clin Aesthetic Dermatol. 2016;9:34–41.
   PubMedGoogle Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris–A randomized phase II study. J Dermatol Treat. 2016;27:120–127.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized phase III study (PSO-FAST). J Drugs Dermatol JDD. 2015;14:1468–1477.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health-related quality of life in patients with psoriasis vulgaris: results from the randomized PSO-FAST study. J Drugs Dermatol JDD. 2016;15:981–987.
   PubMed Web of Science ®Google Scholar
• Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol JEADV. 2019;33:1116–1123.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol JEADV. 2017;31:119–126.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold LF, Cambazard F. More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO-ABLE study in patients with psoriasis vulgaris). J Am Acad Dermatol. 2016;74:AB260.
   Web of Science ®Google Scholar
• Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18:405–411.
   PubMed Web of Science ®Google Scholar
• Jalili A, Lebwohl M, Stein Gold L, et al. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. J Eur Acad Dermatol Venereol JEADV. 2019;33:709–717.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Edwards PH, Harding KG. “Fingertip unit” in dermatology. Lancet Lond Engl. 1989;2:155.
   PubMed Web of Science ®Google Scholar
• Finlay AY. Avoiding palmar ambiguity in the PREPI: a handprint is approximately 1% body surface area. Br J Dermatol. 2011;164:679; author reply 680.
   PubMed Web of Science ®Google Scholar
• Homayoon D, Dahlhoff P, Augustin M. [Adequate prescription and application of topicals : how to calculate the right volume for the prescription of ointment needed?]. Hautarzt Z Dermatol Venerol Verwandte Geb. 2018;69:478–483.
   PubMed Web of Science ®Google Scholar
• Rhodes J, Clay C, Phillips M. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis. Br J Dermatol. 2013;169:76–84.
   PubMed Web of Science ®Google Scholar
• Enstilar cutaneous Foam - Summary of Product Characteristics (SmPC) - (emc) [Internet]. [cited 2020 Jan 27]. Available from: https://www.medicines.org.uk/emc/medicine/31833.
   Google Scholar
• Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Krakor M, Anger T, et al. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatol Basel Switz. 2017;233:425–434.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Veverka KA, Lu M, et al. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. J Dermatol Treat. 2019;30:454–460.
   PubMed Web of Science ®Google Scholar
• Gallo L, Megna M, Cirillo T, et al. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. J Eur Acad Dermatol Venereol JEADV. 2019;33:1312–1315.
   PubMed Web of Science ®Google Scholar
• Giovene GL, Giacomelli L, AIDA (Italian Association of Outpatient Dermatologists) Working Group. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice? G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2018;153:872–876.
   PubMed Web of Science ®Google Scholar
• Dattola A, Silvestri M, Bennardo L, et al. A novel vehicle for the treatment of psoriasis. Dermatol Ther. 2019;33:e13185.
   PubMed Web of Science ®Google Scholar
• Bagel J, Zapata J, Nelson E. An open-label observational study evaluating calcipotriene/betamethasone dipropionate foam in psoriasis patients being treated with biologic agents. J Am Acad Dermatol. 2018;79:AB39..
   Web of Science ®Google Scholar
• Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018;17:845–850.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Belinchón I, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:488–496.
   PubMedGoogle Scholar
• Hong C-H, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol JEADV. 2017;31:1876–1883.
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim BR, Youn SW. Adherence to Topical Therapies for the Treatment of Psoriasis: surveys of Physicians and Patients. Ann Dermatol. 2017;29:559–564.
   PubMed Web of Science ®Google Scholar
• Gorelick J, Cantrell W, Kucera K, et al. Patient-reported satisfaction with the fixed combination calcipotriene/betamethasone dipropionate foam for plaque psoriasis. J Drugs Dermatol. 2018;17:880–884.
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306:719–729.
   PubMed Web of Science ®Google Scholar
• Hashim PW, Nia JK, Terrano D, et al. A comparative study to evaluate epidermal barrier integrity of psoriasis patients treated with calcipotriene/betamethasone topical suspension versus betamethasone dipropionate 0.05% lotion. J Drugs Dermatol JDD. 2017;16:747–752.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Liljedahl M, Clonier F, et al. Phase 1 evaluation of the dermal safety of the fixed combination calcipotriene plus betamethasone dipropionate aerosol foam and foam vehicle. Journal of the American Academy of Dermatology. 2015;72(5):AB211.
   Web of Science ®Google Scholar
• DailyMed - ENSTILAR- calcipotriene and betamethasone dipropionate aerosol, foam [Internet]. [cited 2019 Nov 27]. Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1193df2-d53f-4342-bd9d-d9cba7c89709.
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy of once daily topical treatment with LEO 90100 aerosol foam in adolescent subjects with plaque psoriasis. [Internet]. [cited 2019 Dec 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02387853.
   Google Scholar
• Queille-Roussel C, Rosen M, Clonier F, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate aerosol foam compared with betamethasone 17-valerate-medicated plaster for the treatment of psoriasis. Clin Drug Investig. 2017;37:355–361.
   PubMed Web of Science ®Google Scholar
• Patel NU, Felix K, Reimer D, et al. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017;10:385–391.
   PubMed Web of Science ®Google Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol JEADV. 2012;26(Suppl 3):61–67..
   PubMed Web of Science ®Google Scholar
• Puig L, Carretero G. Update on topical treatments for psoriasis: the role of calcipotriol plus betamethasone dipropionate aerosol foam. Actas Dermosifiliogr. 2019;110:115–123.
   PubMed Web of Science ®Google Scholar
• Kuehl B, Shear NH. The evolution of topical formulations in psoriasis. Skin Ther Lett. 2018;23:5–9.
   PubMedGoogle Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol JEADV. 2015;29:2349–2355.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Belinchón I, et al. Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermo-Sifiliográficas. 2013;104:488–496.
   PubMedGoogle Scholar
• Svendsen MT, Feldmann S, Tiedemann SN, et al. Improving psoriasis patients’ adherence to topical drugs: a systematic review. J Dermatol Treat. 2019;14:1–10.
   Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Andersen KH, et al. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial. BMC Dermatol. 2018;18:2.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. PSOREAL - Managing PSOriasis in the REAL World. [Internet]. [cited 2019 Nov 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02935582.
   Google Scholar